Guidelines for Management of Ischaemic Stroke 2008 European Stroke Org.

At least the Europeans have something like this published and available to the public, if the US has something similar it is well hidden. 151 pages of powerpoint, page 125 has this: Calling it by the milquetoast name of neuroprotection, rather than the more alarming and correct- stopping the neuronal cascade of death. If we don't use the term death, we aren't assigning enough priority to finding a solution to it.

Darn, the URL doesn't exist anymore.

•No adequately sized trial has yet shown significant effect in predefined endpoints for any neuroprotective substance
•A meta-analysis has suggested a mild benefit for citocoline1

Then why is edaravone approved in Japan(since 2001)?

http://www.google.co.in/url?sa=t&rct=j&q=best%20physiotherapy%20approach%20for%20stroke&source=web&cd=76&ved=0CEcQFjAFOEY&url=http%3A%2F%2Fwww.eso-stroke.org%2Fppt%2FESO08_Slides_25thApril.PPT&ei=wbgIT-6HDIatgwes78mzAw&usg=AFQjCNFmHw0837aCyxT_OWd4Kvc2Sk6QJA&cad=rja
And on page 145 they also use the worthless term;

•Multidisciplinary stroke team for rehabilitation

In all these pages they never once listed all the problems that need to be corrected in stroke research, rehabilitation.